News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) Reports Third-Quarter 2012 Results



10/24/2012 10:21:26 AM

Worldwide revenue declined 11 percent to $5.443 billion, driven by Zyprexa patent expirations. Cymbalta revenue increased 16 percent due to continued growth in both the U.S. and international markets.

Read at Sacramento Bee


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES